- Home
- IMTX vs LQDA Comparison
IMTX vs LQDA Comparison
Compare IMTX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- LQDA
- Stock Information
- Founded
- IMTX N/A
- LQDA 2004
- Country
- IMTX Germany
- LQDA United States
- Employees
- IMTX N/A
- LQDA N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- LQDA Health Care
- Exchange
- IMTX Nasdaq
- LQDA Nasdaq
- Market Cap
- IMTX 954.2M
- LQDA 957.2M
- IPO Year
- IMTX N/A
- LQDA 2018
- Fundamental
- Price
- IMTX $5.35
- LQDA $12.89
- Analyst Decision
- IMTX Strong Buy
- LQDA Strong Buy
- Analyst Count
- IMTX 4
- LQDA 7
- Target Price
- IMTX $16.67
- LQDA $26.67
- AVG Volume (30 Days)
- IMTX 988.8K
- LQDA 794.1K
- Earning Date
- IMTX 11-18-2024
- LQDA 03-12-2025
- Dividend Yield
- IMTX N/A
- LQDA N/A
- EPS Growth
- IMTX N/A
- LQDA N/A
- EPS
- IMTX N/A
- LQDA N/A
- Revenue
- IMTX $128,824,447.00
- LQDA $15,610,000.00
- Revenue This Year
- IMTX $116.22
- LQDA N/A
- Revenue Next Year
- IMTX N/A
- LQDA $213.65
- P/E Ratio
- IMTX N/A
- LQDA N/A
- Revenue Growth
- IMTX 52.53
- LQDA N/A
- 52 Week Low
- IMTX $5.28
- LQDA $8.26
- 52 Week High
- IMTX $13.77
- LQDA $16.99
- Technical
- Relative Strength Index (RSI)
- IMTX 21.22
- LQDA 64.85
- Support Level
- IMTX $7.00
- LQDA $11.34
- Resistance Level
- IMTX $7.42
- LQDA $12.58
- Average True Range (ATR)
- IMTX 0.41
- LQDA 0.48
- MACD
- IMTX -0.14
- LQDA 0.05
- Stochastic Oscillator
- IMTX 2.90
- LQDA 97.48
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.